Poxvirus Vector and Anti-PD-L1 Antibody Combination for HPV Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV-positive cancers, particularly squamous cell carcinoma of the head and neck (SCCHN), lack effective therapeutic options that improve anti-tumor efficacy and response rates, with existing combinations of poxvirus vectors and anti-PD-L1 antibodies showing untested toxicity profiles and limited therapeutic efficiency.
Innovation Solution
A combination therapy involving a poxvirus vector encoding human papillomavirus (HPV) E6 and E7 polypeptides and an immunostimulatory cytokine, such as TG4001, administered with an anti-PD-L1 antibody like avelumab, where the poxvirus is given 5 to 10 days before the first anti-PD-L1 antibody administration, and subsequent doses are staggered to minimize toxicity and enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a combination of poxvirus vector and anti-PD-L1 antibody is administered, then immune response and anti-tumor efficacy are improved, but toxicity risks increase due to untested combination profiles
Solution Approach 1:
The poxvirus vector is administered 5 to 10 days before the first anti-PD-L1 antibody administration, allowing the vaccine to prime the immune system and establish a baseline immune response before the checkpoint inhibitor is introduced. This sequential approach enables monitoring and management of toxicity risks while maintaining therapeutic benefits.
Solution Approach 2:
Subsequent administrations of poxvirus and anti-PD-L1 antibody are staggered with specific intervals, creating a periodic treatment schedule that allows the immune system to respond to each administration while providing opportunities to manage and mitigate toxicity between doses.
2Productivity
If poxvirus and anti-PD-L1 antibody are administered simultaneously, then treatment efficiency is improved, but toxicity becomes difficult to manage
Solution Approach 1:
The poxvirus vector is given before the anti-PD-L1 antibody to establish a primed immune state, allowing subsequent antibody administrations to be more effective at lower doses, thereby maintaining treatment efficiency while reducing toxicity burden.
Solution Approach 2:
The treatment is divided into distinct phases: initial poxvirus priming phase followed by anti-PD-L1 antibody treatment phase, with specific timing intervals between administrations. This segmentation allows independent optimization of each component's dosing schedule to balance efficacy and toxicity.
3Reliability
If higher doses of poxvirus and anti-PD-L1 antibody are administered, then immune response is enhanced, but adverse events increase
Solution Approach 1:
The poxvirus vector primes the immune system at lower doses before anti-PD-L1 antibody administration, creating an amplified immune response that allows subsequent antibody treatments to achieve therapeutic effects at reduced dosages, thereby minimizing adverse events while maintaining immune response efficacy.
Solution Approach 2:
The poxvirus administration provides an excessive immune stimulation that primes the system beyond what would be achieved with antibody alone, allowing the subsequent antibody treatment to work more efficiently at lower doses, thus balancing immune response enhancement with reduced toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy induces an improved immune response, increasing CD8 T cells and decreasing regulatory T cells within the tumor, leading to a 'hot' tumor profile and better prognosis, with additive or synergistic potentiating effects, and is well-tolerated, as demonstrated in clinical trials.
Implementation Method 1
a poxvirus vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides
Implementation Method 2
an anti-PD-L1 antibody or antigen-binding fragment thereof
Data Source
AI summary
The present invention relates to a combination of a) a poxvirus vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and an immunostimulatory cytokine, and b) an anti-PD-L1 antibody or antigen-binding fragment thereof, for use in the treatment of an HPV-positive cancer, wherein a first administration of said poxvirus is performed 5 to 10 days before the first administration of said anti-PD-L1 antibody, and subsequent administrations of said poxvirus and anti-PD-L1 antibody are performed.